Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eplerenone for Hypertension in Dialysis Patients
NCT00553722Phase 4
Key facts
- Status
- Unknown
- Start
- Nov 2007
- Countries
- 1
- Sponsor
- Shaare Zedek Medical Center
- Modality
- Orthosteric Ligands
- Drugs
- eplerenone
- Conditions
- hypertension (HTN)
01
Overview
Phase 4, randomised, double-blind trial of eplerenone in hypertension (HTN), sponsored by Shaare Zedek Medical Center. Primary endpoint: Significant drop in blood pressure at 4 weeks. Status: unknown.
02
Design
- Study design
- RandomizedDouble-blind
03
Who it enrols
Adult hemodialysis patients with hypertension and minimal urine output.
04
Endpoints
Primary
Significant drop in blood pressure
Beyond the preview
Go deeper on NCT00553722.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00553722.